UCB Provides Update on Cimzia for Crohn's Disease and Rheumatoid ... - PipelineReview.com (press release)
March 23, 2007 ABCmoney.co.uk | UCB Provides Update on Cimzia for Crohn's Disease and Rheumatoid ... PipelineReview.com (press release), Spain - UCB plans to file a Biologics License Application (BLA) with the FDA for CIMZIATM in the treatment of rheumatoid arthritis by year end 2007. ... UCB Says FDA Wants New Cimzia Study, Delaying Launch (Update3) |
AtheroGenics Schedules Conference Call and Webcast to Discuss ... - SYS-CON Media
March 23, 2007| AtheroGenics Schedules Conference Call and Webcast to Discuss ... SYS-CON Media, NJ - ... of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. ... |
Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial ... - PipelineReview.com (press release)
March 23, 2007| Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial ... PipelineReview.com (press release), Spain - The PACCE trial investigated a treatment regimen that used dual biologics combined with oxaliplatin- or irinotecan-based chemotherapy. ... |
AtheroGenics Schedules Conference Call and Webcast to Discuss ... - Genetic Engineering News (press release)
March 23, 2007| AtheroGenics Schedules Conference Call and Webcast to Discuss ... Genetic Engineering News (press release), NY - ... of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. ... |
Committee for Medicinal Products for Human Use Summary of Positive ... - PharmaLive.com (press release)
March 23, 2007| Committee for Medicinal Products for Human Use Summary of Positive ... PharmaLive.com (press release), PA - Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis. ... |
EU panel backs Bristol-Myers arthritis drug - Reuters
March 23, 2007| EU panel backs Bristol-Myers arthritis drug Reuters - N: Quote, Profile, Research) Orencia as a treatment for moderate to severe rheumatoid arthritis. Recommendations for marketing approval from the European ... |
Meeting Highlights From The Committee For Medicinal Products For ... - Medical News Today (press release)
March 23, 2007| Meeting Highlights From The Committee For Medicinal Products For ... Medical News Today (press release), UK - It is currently indicated for the treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, psoriasis and ulcerative ... |
Research On Stem Cell Research - BioResearch Online (press release)
March 23, 2007| Research On Stem Cell Research BioResearch Online (press release), PA - Parkinson’s disease, leukemia, heart disease, rheumatoid arthritis, and type I diabetes are a few striking examples of devastating diseases, many of us are ... |
UCB Provides Update on Cimzia for Crohn's Disease and Rheumatoid ... - PharmaLive.com (press release)
March 23, 2007| UCB Provides Update on Cimzia for Crohn's Disease and Rheumatoid ... PharmaLive.com (press release), PA - UCB plans to file a Biologics License Application (BLA) with the FDA for CIMZIATM in the treatment of rheumatoid arthritis by year end 2007. ... |
UCB To Initiate Additional Short-term Clinical Study Of CIMZIATM ... - Trading Markets
March 23, 2007| UCB To Initiate Additional Short-term Clinical Study Of CIMZIATM ... Trading Markets, CA - Further, by the end of 2007, UCB plans to file a Biologics License Application with the FDA for CIMZIATM in the treatment of rheumatoid arthritis. |
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and ... - SYS-CON Media
March 23, 2007ABCmoney.co.uk | UCB Provides Update on CIMZIA(TM) for Crohn's Disease and ... SYS-CON Media, NJ - UCB plans to file a Biologics License Application (BLA) with the FDA for CIMZIATM in the treatment of rheumatoid arthritis by year end 2007. ... UCB Says FDA Wants New Cimzia Study, Delaying Launch (Update3) UCB To Initiate Additional Short-term Clinical Study Of CIMZIATM ... UCB to launch clinical study for Cimzia to to meet FDA demands |
Amgen Discontinues Vectibix Treatment in PACCE Trial Evaluating ... - PharmaLive.com (press release)
March 23, 2007| Amgen Discontinues Vectibix Treatment in PACCE Trial Evaluating ... PharmaLive.com (press release), PA - ... helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. ... Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial ... |
Senior R&D Management Promotions at EntreMed Support Current and ... - PharmaLive.com (press release)
March 23, 2007| Senior R&D Management Promotions at EntreMed Support Current and ... PharmaLive.com (press release), PA - ... cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. ... |
Senior R&D Management Promotions at EntreMed Support Current and ... - PR Newswire (press release)
March 23, 2007| Senior R&D Management Promotions at EntreMed Support Current and ... PR Newswire (press release), NY - ... cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. ... |
Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial ... - Newsdesk
March 23, 2007| Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial ... Newsdesk, Sweden - The PACCE trial investigated a treatment regimen that used dual biologics combined with oxaliplatin- or irinotecan-based chemotherapy. ... |
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and ... - WM Experts (press release)
March 23, 2007| UCB Provides Update on CIMZIA(TM) for Crohn's Disease and ... WM Experts (press release), FL - UCB plans to file a Biologics License Application (BLA) with the FDA for CIMZIATM in the treatment of rheumatoid arthritis by year end 2007. ... |